ASX:RACPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Racura Oncology Ltd
$2.140
Day Range
$2.140 – $2.140
52 Week Range
$1.335 – $4.900
Volume
0.00
Avg Volume (10D)
75.45K
Price Chart
OHLC · volume · moving averages
$2.140-$0.140 (-6.14%)over 6M
Hi$3.600Lo$1.910Avg Vol147.3K
Price-sensitive newsVolumePrev close · 52W rangeDrag the handles below to zoom
Market Statistics
Today's trading range
Open
$2.140
Previous Close
$2.140
Day High
$2.140
Day Low
$2.140
52 Week High
$4.900
52 Week Low
$1.335
Valuation
Fundamental multiples
Market Cap
0.00
Shares Outstanding
0.00
Price to Book
12.05
Trading Activity
Volume & order book
Volume
0.00
Value Traded
0.00
Bid
$2.130 × 11,127
Ask
$2.140 × 1,288
Performance
Returns across timeframes
1 Day
5.16%
5 Day
5.66%
13 Week
-9.68%
52 Week
78.49%
YTD
-17.95%
Technical Indicators
Momentum & moving averages
RSI (14)
50.95
50-Day SMA
$2.114
200-Day SMA
$2.471
— From the desk
Latest News
Biotechnology
Racura Oncology Opens Korean Recruitment for RC220 Phase 1 Solid Tumours Trial
Racura Oncology opens Korea recruitment for RC220 Phase 1 solid tumours trial, expanding to Ewha, Severance and Samsung Medical Center to accelerate enrolment.
Biotechnology
Racura Oncology Treats First Patient in Harness-1 EGFRm Lung Cancer Trial
Racura Oncology starts Harness-1 Phase 1 with first patient dosed for RC220 + osimertinib in EGFR-mutant NSCLC; early safety data awaited.
Biotechnology
Racura Oncology Advances CPACS Trial to Next Dose Level
Racura Oncology advances RC220 CPACS trial to 80mg/m2 as SRC clears Cohort 2; updated cardioprotection protocol; A$19.38m cash runway to CY2027.
Biotechnology
Racura Oncology Advances Lung Cancer Program with HARNESS-1 Trial Approval
Racura Oncology wins HARNESS-1 Phase 1a/b governance approval for RC220/osimertinib in EGFR-mutant NSCLC, enabling site initiation and recruitment.